The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes

Am J Physiol Heart Circ Physiol. 2015 Apr 1;308(7):H749-58. doi: 10.1152/ajpheart.00414.2014. Epub 2015 Jan 23.

Abstract

AMP kinase (AMPK) plays an important role in the regulation of energy metabolism in cardiac cells. Furthermore, activation of AMPK protects the heart from myocardial infarction and heart failure. The present study examines whether or not AMPK affects the peroxisome proliferator-activated receptor-α (PPARα)/mitochondria pathway in response to acute oxidative stress in cultured cardiomyocytes. Cultured H9c2 rat embryonic cardioblasts were exposed to H2O2-induced acute oxidative stress in the presence or absence of metformin, compound C (AMPK inhibitor), GW6471 (PPARα inhibitor), or A-769662 (AMPK activator). Results showed that AMPK activation by metformin reverted oxidative stress-induced inactivation of AMPK and prevented oxidative stress-induced cell death. In addition, metformin attenuated reactive oxygen species generation and depolarization of the inner mitochondrial membrane. The antioxidative effects of metformin were associated with the prevention of mitochondrial DNA damage in cardiomyocytes. Coimmunoprecipitation studies revealed that metformin abolished oxidative stress-induced physical interactions between PPARα and cyclophilin D (CypD), and the abolishment of these interactions was associated with inhibition of permeability transition pore formation. The beneficial effects of metformin were not due to acetylation or phosphorylation of PPARα in response to oxidative stress. In conclusion, this study demonstrates that the protective effects of metformin-induced AMPK activation against oxidative stress converge on mitochondria and are mediated, at least in part, through the dissociation of PPARα-CypD interactions, independent of phosphorylation and acetylation of PPARα and CypD.

Keywords: AMPK; H9c2 cardiomyocytes; PPARα; metformin; mitochondria; oxidative stress.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenylate Kinase / antagonists & inhibitors
  • Adenylate Kinase / metabolism*
  • Animals
  • Antioxidants / pharmacology*
  • Biphenyl Compounds
  • Cell Death / drug effects
  • Cell Line
  • Cyclophilins / metabolism*
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Enzyme Activators / pharmacology*
  • Membrane Potential, Mitochondrial / drug effects
  • Metformin / pharmacology*
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / enzymology
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Permeability Transition Pore
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / pathology
  • Oxidants / pharmacology
  • Oxidative Stress / drug effects*
  • PPAR alpha / antagonists & inhibitors
  • PPAR alpha / metabolism*
  • Protein Binding
  • Protein Kinase Inhibitors / pharmacology
  • Pyrones / pharmacology
  • Rats
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Thiophenes / pharmacology

Substances

  • Antioxidants
  • Biphenyl Compounds
  • Enzyme Activators
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Oxidants
  • PPAR alpha
  • Protein Kinase Inhibitors
  • Pyrones
  • Reactive Oxygen Species
  • Thiophenes
  • Metformin
  • Adenylate Kinase
  • Cyclophilins
  • Ppid protein, rat
  • 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile